Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773495 · ClinicalTrials.gov registry record · NA
Implementation of Teleophthalmology in Urban Health Systems Study
A NA study of Diabetic Retinopathy, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- NA
- Development phase
- 12,840
- Enrollment target
- 1
- Study location
NCT05773495: Active NA study of Diabetic Retinopathy, sponsored by University of Wisconsin, Madison.
NCT05773495 is a NA study of Diabetic Retinopathy that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 12,840 participants, above the 1,451-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (785% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05773495, a NA study of Diabetic Retinopathy, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12,840 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to test the effectiveness of I-SITE (Implementation for Sustained Impact in Teleophthalmology), an implementation program to sustain increased diabetic eye screening rates using teleophthalmology in urban, multi-payer health systems.
Primary Outcome
Proportion of patients with diabetes with medical record documentation of diabetic eye screening within the last 12 months among patients with type 1 or type 2 diabetes who had at least 2 clinic visits with primary care provider within the past 24 months.
Conditions Studied
Interventions
- OTHER I-SITE Intervention
- OTHER Usual Care Teleophthalmology
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,840 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What the registry record for NCT05773495 still lists
NCT05773495 is an interventional study that assigns participants to a tested intervention. Its 12,840 participants enrollment target places it among the larger protocols in the corpus, above the 1,451-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (785% higher).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which I-SITE Intervention is the first listed.
NCT05773495 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05773495 about?
NCT05773495 is a clinical study titled "Implementation of Teleophthalmology in Urban Health Systems Study". This study is being conducted to test the effectiveness of I-SITE (Implementation for Sustained Impact in Teleophthalmology), an implementation program to sustain increased diabetic eye screening rates using teleophthalmology in urban, multi-payer health systems.
What is the current status of trial NCT05773495?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12,840 participants. The study started on 2024-03-19. Estimated completion is 2028-12-31.
What conditions does trial NCT05773495 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT05773495?
The interventions under investigation include: I-SITE Intervention (OTHER), Usual Care Teleophthalmology (OTHER).
Who is sponsoring clinical trial NCT05773495?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05773495 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05773495's enrollment target sits among peer trials
12,840 2nd of 57 the highest of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
RECRUITING · NA
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
ACTIVE NOT RECRUITING · NA
-
Circadian Amplification in Diabetic Retinopathy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI